Frankfurt
12.05.26 | 08:05
0,164 Euro
+0,86 % +0,001
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,171 | 0,187 | 12.05. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04.05. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 220 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| MAUNA KEA TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 30.04. | Mauna Kea Technologies: Publication of the 2025 Annual Financial Report | 194 | Business Wire | Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced... ► Artikel lesen | |
| 28.04. | Mauna Kea Technologies Announces Expanded Clinical Evidence for Cellvizio To Be Presented at Digestive Disease Week 2026 | 440 | Business Wire | 10 Cellvizio-related abstracts, including landmark multicenter pancreatic cyst data, AI-driven IBD assessment, and new food intolerance applications, reinforce the breadth and depth of real-time... ► Artikel lesen | |
| 22.04. | Mauna Kea Technologies meldet starkes Wachstum im ersten Quartal 2026 | 1 | Investing.com Deutsch | ||
| 22.04. | Mauna Kea Technologies Reports FY 2025 Financial Results: Comprehensive Debt Restructuring and Reaccelerating Organic Growth Mark a Transformative 2025 | 707 | Business Wire | Fundamental balance sheet reset achieved through a 70% reduction in financial debt and €20M increase in equity Product sales momentum in 2025 driven by record U.S. sales performance (+38% CER)... ► Artikel lesen | |
| 15.04. | Mauna Kea Technologies Reports Strong Q1 2026 Core Sales Growth | 349 | Business Wire | Q1 2026 sales reached €1,527K (excluding licensing), an increase of +68% at Constant Exchange Rate CER) and +57% as reported U.S. sales grew +34% CER (+21% reported) and +51% on an invoiced basis... ► Artikel lesen | |
| 08.04. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 248 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 17.03. | Mauna Kea Technologies Updates Its Financial Calendar | 1.053 | Business Wire | Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today... ► Artikel lesen | |
| 23.02. | Mauna Kea Technologies Accelerates International Expansion with New Regulatory Clearances in Switzerland and the United Kingdom | 1.038 | Business Wire | These clearances enable the commercialization of Cellvizio in two major markets and accelerate the Group's international expansion First order for the next-generation Cellvizio (Gen 3) platform... ► Artikel lesen | |
| 10.02. | Mauna Kea Technologies Announces CE MDR Certification For Cellvizio and Its Associated Probes | 459 | Business Wire | A major regulatory milestone in the European commercial expansion strategy Mauna Kea Technologies is the only endomicroscopy company to obtain this certification under the new European regulation
Regulatory... ► Artikel lesen | |
| 06.02. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 480 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 04.02. | Mauna Kea Technologies Announces New Commercial Organization to Accelerate Growth Outside the United States | 635 | Business Wire | Building on Strong 2025 Momentum with Accelerated Sales Growth in Pancreatic Cysts €1M Milestone for CellTolerance Appointment of Benoit Chardon as Fractional Chief Commercial Officer to Lead... ► Artikel lesen | |
| 26.01. | Mauna Kea Technologies Announces Initiation of Coverage by Allinvest Securities | 325 | Business Wire | Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) announces today... ► Artikel lesen | |
| 21.01. | Mauna Kea Technologies Announces Its 2026 Financial Calendar Highlighted by Its Participation in Several Investor Forums | 711 | Business Wire | Regulatory News:
Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today... ► Artikel lesen | |
| 15.01. | Mauna Kea Technologies Reports Strong Q4 2025 Sales Driven by Accelerated Growth in the U.S. | 1.323 | Business Wire | Q4 2025 revenue up 19% on a reported basis (+29% excluding currency effects CER) Sales in the United States up 65% (+82% at CER) after three consecutive quarters of acceleration (+11%, +23%,... ► Artikel lesen | |
| 09.01. | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 390 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 05.12.25 | Mauna Kea Technologies: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital | 467 | Business Wire | Article L233-8-II of the Commercial Code
Article 223-16 of the General Regulations of the AMF
Regulatory News:
Mauna Kea Technologies (Paris:ALMKT):
Listing: Euronext Growth Paris
ISIN... ► Artikel lesen | |
| 03.12.25 | Mauna Kea Technologies and TaeWoong Medical USA Announce Exclusive Partnership to Accelerate Commercial Expansion in the U.S. in Pancreatic Cyst Management | 530 | Business Wire | Integrating Cellvizio into TaeWoong's portfolio of therapeutic devices to create the first fully integrated "imaging-to-therapy" solution for EUS-guided pancreatic care
Regulatory News:
Mauna... ► Artikel lesen | |
| 20.11.25 | Mauna Kea Technologies Receives NMPA Regulatory Approval in China for its Next-Generation Cellvizio Platform | 1.650 | Business Wire | NMPA approval obtained following a 3-year certification process Mauna Kea is now evaluating options to commercialize Cellvizio Gen 3 in China independently of the JV with Tasly
Regulatory... ► Artikel lesen | |
| 17.11.25 | XFRA 1MK: WIEDERAUFNAHME/RESUMPTION | 344 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen |
1 2 3 Weiter >>
49 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SERNOVA BIOTHERAPEUTICS | 0,094 | -0,21 % | Sernova Biotherapeutics: Sernova Biotherapeutics Announces Closing of Recently Approved Financings | Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - April 23, 2026) - Sernova Biotherapeutics (TSX: SVA) (OTC: SEOVF) (FSE: PSHO) (XETRA: PSHO) ("Sernova" or the "Company"), a leading... ► Artikel lesen | |
| FAMICORD | 4,090 | 0,00 % | FAMICORD AG - Schwäche als Prüfstein der Substanz | ||
| GERATHERM MEDICAL | 2,750 | 0,00 % | Geratherm Medical wechselt vom Börsensegment Scale in den Open Market | Die Geratherm Medical AG beendet zum 27. April 2026 die Einbeziehung ihrer Aktien in das Börsensegment Scale der Frankfurter Wertpapierbörse und wechselt ins Basic Board am Open Market. Die Börsennotierung... ► Artikel lesen | |
| PLUS THERAPEUTICS | 5,190 | 0,00 % | Plus Therapeutics Inc.: Plus Therapeutics Receives Medicare Enrollment Approval for CNSide Diagnostic | HOUSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals... ► Artikel lesen | |
| MEDICLIN | 3,580 | 0,00 % | EQS-News: MEDICLIN AG: MEDICLIN steigert Betriebsergebnis im ersten Quartal | EQS-News: MEDICLIN AG
/ Schlagwort(e): Quartals-/Zwischenmitteilung
MEDICLIN steigert Betriebsergebnis im ersten Quartal
04.05.2026 / 13:08 CET/CEST
Für den Inhalt der... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 4,680 | -0,43 % | Atossa Therapeutics Inc: Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update | SEATTLE, May 8, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Reports Financial Results for Third Quarter of 2025, Provides Business Update | -- Increased Net Sales 10% While Lowering Operating Expenses 42% vs. Prior Year Quarter --
-- Delivered $1.0 Million of Operating Income in Q3 2025 --
SAN DIEGO... ► Artikel lesen | |
| SONOMA PHARMACEUTICALS | 2,350 | -100,00 % | Sonoma Pharmaceuticals: 150.000 Aktien gekauft - das ist der Grund! | Die Aktie von Sonoma Pharmaceuticals ist Zockern aus der sharedeals.de-Community seit Jahren bekannt. Mehrfach wurden dreistellige Kurs-Peaks innerhalb kürzester Zeit für herausragend lukrative Trading-Exits... ► Artikel lesen | |
| NOVACCESS GLOBAL | - | - | NovAccess Global Inc. - 10-K, Annual Report | ||
| VERU | 2,270 | +2,71 % | Veru Inc.: Veru to Report Fiscal 2026 Second Quarter Financial Results on May 13th | ||
| LIFEWARD | 6,480 | +1,25 % | Lifeward Ltd.: Lifeward to Report First Quarter 2026 Financial Results on May 15, 2026 | ||
| LIGHT AI | 0,095 | +0,64 % | Light AI Inc: Light AI adds Orsmond as CFO; director Attanasio quits | ||
| IMUNON | 2,380 | +3,48 % | Earnings Call Q1 2026: Imunon meldet Fortschritte bei klinischer Studie und hohe Kostendisziplin | ||
| FRESENIUS | 39,520 | -0,90 % | Börse am Morgen: AMD, Fresenius, Infineon, Renk, Konjunkturdaten - Nord/LB | Die Erzeugerpreise in der Industrie im Euroraum sind mit Beginn des Nahost-Krieges deutlich gestiegen. Im März kletterten sie um 3,4% zum Vormonat. Allein die Energiepreise in der Industrie zogen im... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 33,900 | +0,98 % | Börse am Morgen: Continental, Henkel, Siemens Healthineers, Konjunkturdaten - Nord/LB | Die deutsche Industrie hat im ersten Monat nach Beginn des Iran-Kriegs überraschend viele Aufträge erhalten. Das Neugeschäft wuchs im März um 5,0% im Vergleich zum Vormonat, wie das Statistische Bundesamt... ► Artikel lesen |
MAUNA KEA TECHNOLOGIES gehört der Branche Gesundheitswesen an. Die relative Kursveränderung beträgt aktuell +0,86 % bei einem Aktienkurs von 0,164 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MAUNA KEA TECHNOLOGIES finden Sie auf Wallstreet Online.